Evidence map›Paper›PMID 28413217›Full record

ReviewCellular & molecular immunology2017

Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Haidong Tang, Mingzhao Zhu, Jian Qiao, Yang-Xin Fu

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular & molecular immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Dural ectopic lymphatic structures accumulate during aging and exhibit dysregulation in neurodegenerative diseases.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Haidong TangDepartment of Pathology, University of Texas, Southwestern Medical Center, Dallas, TX 75235, USA.
Mingzhao ZhuIBP-UTSW Joint Immunotherapy Group, Chinese Academy of Science, Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Jian QiaoDepartment of Pathology, University of Texas, Southwestern Medical Center, Dallas, TX 75235, USA.
Yang-Xin FuDepartment of Pathology, University of Texas, Southwestern Medical Center, Dallas, TX 75235, USA.
Institute of Biophysics · CNThe University of Texas Southwestern Medical Center · US

Funding

Protein Expression and Peptide CoreP01CA097296 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 2003 to 2012
$15.0M
TNF family members for lymph angiogenesis and lymph node hypertrophyR01CA141975 · NCI · UNIVERSITY OF CHICAGO · PI FU, YANG-XIN · 2010 to 2014
$1.6M
NCI NIH HHS P01 CA097296NCI NIH HHS R01 CA141975
6 · The paper itself

Abstract

Tertiary lymphoid structures (TLS) often develop at sites of persistent inflammation, including cancers and autoimmune diseases. In most cases, the presence of TLS correlates with active immune responses. Because of their proximity to pathological loci, TLS are an intriguing target for the manipulation of immune responses. For several years, it has become clear that lymphotoxin (LT) signalling plays critical roles in lymphoid tissue organogenesis and maintenance. In the current review, we will discuss the role of LT signalling in the development of TLS. With a focus on cancers and autoimmune diseases, we will highlight the correlations between TLS and disease progression. We will also discuss the current efforts and potential directions for manipulating TLS for immunotherapies.

Indexed as

AnimalsAutoimmune DiseasesCarcinogenesisDisease ProgressionHumansImmunotherapyLymphoid TissueLymphotoxin-alphaNeoplasmsOrganogenesisSignal TransductionTertiary Lymphoid StructuresLymphotoxin-alpha

Identifiers

PMID28413217
PMCPMC5649108
OpenAlexW2606167786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.